EA201491747A1 - Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов - Google Patents

Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов

Info

Publication number
EA201491747A1
EA201491747A1 EA201491747A EA201491747A EA201491747A1 EA 201491747 A1 EA201491747 A1 EA 201491747A1 EA 201491747 A EA201491747 A EA 201491747A EA 201491747 A EA201491747 A EA 201491747A EA 201491747 A1 EA201491747 A1 EA 201491747A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
flt3 inhibitors
substituted pyridopyrimidine
compounds
pyridopyrimidine compounds
Prior art date
Application number
EA201491747A
Other languages
English (en)
Other versions
EA031267B1 (ru
Inventor
Хонг Ву Ким
Хи Киу Ли
Хо-Джун Сонг
Джаекиу Ли
Джонг Сунг Кох
Джунг-хо Ким
Се Вон Ким
Ин Йонг Ли
Original Assignee
Джиноско
Оскотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джиноско, Оскотек, Инк. filed Critical Джиноско
Publication of EA201491747A1 publication Critical patent/EA201491747A1/ru
Publication of EA031267B1 publication Critical patent/EA031267B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Раскрываются соединения формулы (I) и способы ингибирования киназ, включая тирозинкиназы селезенки. Также раскрываются способы лечения киназа-опосредованного заболевания или состояния посредством введения субъекту терапевтически эффективного количества соединения формулы (I).
EA201491747A 2012-03-22 2013-03-15 Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов EA031267B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261614274P 2012-03-22 2012-03-22
PCT/US2013/032575 WO2013142382A1 (en) 2012-03-22 2013-03-15 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors

Publications (2)

Publication Number Publication Date
EA201491747A1 true EA201491747A1 (ru) 2015-10-30
EA031267B1 EA031267B1 (ru) 2018-12-28

Family

ID=49223277

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491747A EA031267B1 (ru) 2012-03-22 2013-03-15 Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов

Country Status (22)

Country Link
US (1) US8877763B2 (ru)
EP (1) EP2828259B1 (ru)
JP (1) JP6101341B2 (ru)
KR (1) KR102011770B1 (ru)
CN (1) CN104428298B (ru)
AU (1) AU2013235344B2 (ru)
BR (1) BR112014023460B1 (ru)
CA (1) CA2868156C (ru)
CL (1) CL2014002505A1 (ru)
EA (1) EA031267B1 (ru)
ES (1) ES2694223T3 (ru)
HK (1) HK1208453A1 (ru)
IL (1) IL234802B (ru)
IN (1) IN2014MN02082A (ru)
MX (1) MX360912B (ru)
MY (1) MY184858A (ru)
NZ (1) NZ700283A (ru)
PL (1) PL2828259T3 (ru)
SG (1) SG11201405942RA (ru)
TR (1) TR201816480T4 (ru)
WO (1) WO2013142382A1 (ru)
ZA (1) ZA201407588B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3060562T (pt) * 2013-10-21 2021-09-02 Genosco Compostos de pirimidina substituídos e sua utilização como inibidores da syk
JP6665154B2 (ja) * 2014-07-17 2020-03-13 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体及びその薬学的使用
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
KR20170087913A (ko) 2014-11-17 2017-07-31 로드아일랜드하스피틀 나노물질, 조성물, 합성, 및 어셈블리
AU2019292207B2 (en) * 2018-06-27 2022-06-30 Oscotec Inc. Pyridopyrimidinone derivatives for use as Axl inhibitors
KR20200022712A (ko) * 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN110327347B (zh) * 2019-08-16 2021-06-01 陕西科技大学 G-749在制备抗真菌药物中的应用
TWI759829B (zh) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
KR102440707B1 (ko) 2022-07-10 2022-09-05 이우미 공장 추천 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020070520A (ko) * 2000-01-27 2002-09-09 워너-램버트 캄파니 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체
BR0113628A (pt) * 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxo-piridopirimidinas como inibidores de uma proliferação celular
MXPA03001733A (es) * 2000-08-31 2003-05-27 Hoffmann La Roche 7-oxo-piridopirimidinas.
EP2025678A1 (en) * 2007-08-17 2009-02-18 Oncalis AG Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
ES2432414T3 (es) * 2008-08-12 2013-12-03 Glaxosmithkline Llc Compuestos químicos
US8338481B2 (en) * 2009-01-28 2012-12-25 Ramot At Tel-Aviv University Ltd. Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer
JP2013502429A (ja) * 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
CN102695416B (zh) * 2009-10-29 2017-03-08 金纳斯克公司 激酶抑制剂

Also Published As

Publication number Publication date
EP2828259A4 (en) 2015-08-19
CN104428298A (zh) 2015-03-18
JP6101341B2 (ja) 2017-03-22
JP2015510942A (ja) 2015-04-13
EA031267B1 (ru) 2018-12-28
KR20140144709A (ko) 2014-12-19
CN104428298B (zh) 2017-03-01
IL234802B (en) 2018-10-31
IN2014MN02082A (ru) 2015-08-21
TR201816480T4 (tr) 2018-11-21
MY184858A (en) 2021-04-27
US8877763B2 (en) 2014-11-04
AU2013235344B2 (en) 2017-03-16
EP2828259B1 (en) 2018-08-08
EP2828259A1 (en) 2015-01-28
SG11201405942RA (en) 2014-10-30
ZA201407588B (en) 2015-11-25
HK1208453A1 (en) 2016-03-04
MX2014011354A (es) 2014-12-05
CA2868156A1 (en) 2013-09-26
CL2014002505A1 (es) 2015-10-02
US20130274274A1 (en) 2013-10-17
AU2013235344A1 (en) 2014-10-09
BR112014023460B1 (pt) 2020-09-01
MX360912B (es) 2018-11-22
KR102011770B1 (ko) 2019-08-19
CA2868156C (en) 2020-07-28
WO2013142382A1 (en) 2013-09-26
PL2828259T3 (pl) 2019-02-28
NZ700283A (en) 2016-08-26
ES2694223T3 (es) 2018-12-19

Similar Documents

Publication Publication Date Title
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201891553A1 (ru) Ингибиторы syk
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA201690094A1 (ru) Ингибиторы syk
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM